July 31, 2018 07:46 AM EDT
R&D

Rev­enue shrink­ing, Sanofi sweeps a PhII can­cer ADC and TB vac­cine pro­gram out of the pipeline in Q2 cleanup

John Carroll

Editor & Founder

A lit­tle more than a year ago Sanofi $SNY hand­ed Im­muno­Gen a $30 mil­lion pay­ment to gain ex­clu­sive de­vel­op­ment rights to a slate of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

Al­tos Labs buys an­ti-ag­ing start­up Do­ri­an Ther­a­peu­tics

Genen­tech ex­pands deal with mol­e­c­u­lar glue biotech Ori­o­n­is for $105M up­front

How PureTech’s lung fi­bro­sis drug stacks up against the com­pe­ti­tion

Co­caine vac­cine, a long­shot at­tempt to quell crav­ings, yields mixed da­ta in small study

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times